Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, ...
A 2026 review synthesizes plant, enzyme-engineering and microbial approaches to phytosterol production, including a reported engineered-yeast campesterol titer of 5.88 grams per liter.
A 62-day tank trial found that soybean meal and Kappaphycus sp. produced distinct gut bacterial communities in farmed Nile ...
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new Phase III data for investigational fenebrutinib in multiple sclerosis (MS), demonstrating reduced markers of ...
New Phase 2 CALLIPER Open-Label Extension Data Support Durability of Disability Outcomes Observed During the Double-Blind ...
Fenebrutinib trials report 55% lower annualised relapse rates while Roche also presents paediatric Ocrevus and MOGAD Enspryng data Roche has announced new Phase III neuroimmunology data at ...
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) will present new data at IDWeek 2026 that reinforce the role of Fetroja ® ...
Researchers engineered hybrid strontium sulfite nanoparticle-modified lipid nanoparticles to deliver p53 mRNA, producing ...
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") will present new exploratory analyses from the global Phase 3 SCORPIO-PEP study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results